GLP-1 medications are a class of injectable and oral drugs that mimic glucagon-like peptide-1, an incretin hormone the gut releases after eating, to lower blood glucose and reduce appetite. The class has been in clinical use since 2005 and now spans seven molecules across roughly a dozen brand names, approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, obstructive sleep apnea, and chronic kidney disease in type 2 diabetes. They differ substantially in receptor targets, dosing frequency, magnitude of weight loss, and the outcomes data behind each label. This article summarizes the published trial evidence for the class. Advanced TRT Clinic is not affiliated with or endorsed by Novo Nordisk, Eli Lilly, or any other manufacturer.
What GLP-1 Medications Are and How They Work
Glucagon-like peptide-1 is an incretin hormone secreted by intestinal L-cells in response to food. Endogenous GLP-1 circulates briefly — its half-life is a matter of minutes, because the enzyme DPP-4 degrades it almost immediately. GLP-1 receptor agonists are engineered molecules that activate the same receptor but resist that degradation, extending the signal from minutes to hours or days.
Receptor activation produces four effects that matter clinically. It stimulates glucose-dependent insulin secretion, meaning insulin release rises when glucose is elevated and falls when it is not — which is why these drugs carry low intrinsic hypoglycemia risk as monotherapy. It suppresses glucagon secretion, reducing hepatic glucose output. It slows gastric emptying, prolonging satiety after a meal. And it acts on hypothalamic appetite centers to reduce hunger and food-seeking behavior.
The weight loss is a consequence of the last two effects rather than a metabolic accelerant. Patients on GLP-1 therapy eat less because they feel full sooner and stay full longer. This distinction matters when setting expectations: the medication reduces caloric intake, and the outcome still depends on what is eaten and whether lean mass is protected through adequate protein and resistance training.
The same molecule is frequently sold under different brand names for different approved uses, at different doses. Semaglutide is Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as an oral tablet for type 2 diabetes. Liraglutide is Victoza for diabetes and Saxenda for weight management. Tirzepatide is Mounjaro for diabetes and Zepbound for weight management. Prescribing the diabetes brand for weight loss is off-label use, and it affects insurance coverage, dosing, and savings program eligibility. Always confirm which product and indication apply to your situation with a licensed clinician.
The Complete Class: Approved GLP-1 Medications
Seven molecules make up the currently marketed class in the United States. They are listed below by approval date, with the receptor target, dosing schedule, and approved indications for each.
| Molecule | Brand Names | Receptor Target | Dosing | Approved For |
|---|---|---|---|---|
| Exenatide | Byetta | GLP-1 | Twice daily | Type 2 diabetes |
| Liraglutide | Victoza, Saxenda | GLP-1 | Once daily | T2D (Victoza); weight management (Saxenda) |
| Dulaglutide | Trulicity | GLP-1 | Once weekly | Type 2 diabetes; CV risk reduction in T2D |
| Semaglutide (injectable) | Ozempic, Wegovy | GLP-1 | Once weekly | T2D, CV risk, CKD in T2D (Ozempic); weight management, CV risk in obesity, OSA (Wegovy) |
| Semaglutide (oral) | Rybelsus | GLP-1 | Daily tablet | Type 2 diabetes |
| Tirzepatide | Mounjaro, Zepbound | GIP + GLP-1 | Once weekly | T2D (Mounjaro); weight management, OSA in obesity (Zepbound) |
| Exenatide extended-release | Bydureon BCise | GLP-1 | Once weekly | Type 2 diabetes (US availability has changed; confirm current supply) |
Two structural families sit behind these names. Exenatide and lixisenatide derive from exendin-4, a peptide originally identified in Gila monster venom that happens to activate the human GLP-1 receptor. Liraglutide, dulaglutide, and semaglutide are modified versions of human GLP-1 itself, engineered with fatty acid chains or antibody fragments that bind albumin and extend half-life. Tirzepatide is a separate design entirely — a single peptide built to activate two receptors.
Three Generations: Single, Dual, and Triple Agonism
The clearest way to organize the class is by how many incretin receptors each molecule engages. Each added target has produced a measurable step up in efficacy.
Single GLP-1 agonism. Every molecule approved between 2005 and 2021 activates the GLP-1 receptor alone. Within this tier, efficacy still varies considerably — semaglutide 2.4mg produces roughly twice the weight reduction of liraglutide 3.0mg — because potency, half-life, and achievable dose differ between molecules even at an identical target.
Dual GIP/GLP-1 agonism. Tirzepatide added glucose-dependent insulinotropic polypeptide to the picture. GIP is the other major incretin hormone, secreted by intestinal K-cells. GIP receptor activation improves insulin sensitivity in adipose tissue and appears to amplify the hypothalamic response to GLP-1 rather than duplicate it. In rodent models, GIP agonism alone does not produce weight loss, but combined with GLP-1 agonism it substantially increases the effect. That synergy is the mechanistic explanation for the efficacy gap observed in human trials.
Triple agonism. Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 combination. Glucagon receptor activation increases energy expenditure, adding a mechanism the earlier generations did not have. Retatrutide remains investigational and is not FDA-approved. Phase 2 results reported weight reductions exceeding those seen with dual agonism, but phase 3 data and a full safety profile are required before any clinical conclusion can be drawn.
Mean Weight Reduction in Pivotal Weight Management Trials
| Molecule and Dose | Trial | Duration | Mean Weight Reduction |
|---|---|---|---|
| Liraglutide 3.0mg | SCALE Obesity | 56 weeks | Approximately 8% |
| Semaglutide 2.4mg | STEP-1 | 68 weeks | 14.9% |
| Semaglutide 2.4mg | SURMOUNT-5 (comparator arm) | 72 weeks | 13.7% |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | Approximately 20.9% |
| Tirzepatide 10mg or 15mg | SURMOUNT-5 (head-to-head) | 72 weeks | 20.2% |
Figure 1. Results come from separate trials with different populations, protocols, and durations, and are not directly comparable except for SURMOUNT-5, which randomized participants head to head. Individual response varies substantially around these means.
Only SURMOUNT-5 directly compared two GLP-1 medications at full weight management doses in the same randomized population: tirzepatide 20.2% versus semaglutide 13.7% at 72 weeks.
Every other comparison in the table is indirect. SCALE, STEP-1, and SURMOUNT-1 enrolled different populations under different protocols, and placebo-arm weight loss differed between them. Numbers from separate trials suggest a ranking but do not measure one.
Trial means also describe groups, not individuals. Within every arm, some participants lost substantially more than the mean and some lost very little. Prior response to one molecule does not reliably predict response to another.
Beyond Weight and Glucose: The Outcomes Data
The clinical reputation of this class no longer rests on weight and HbA1c alone. Several molecules have cardiovascular outcomes trials behind them, and this is where the class separates most sharply.
Cardiovascular outcomes. LEADER showed liraglutide reduced major adverse cardiovascular events in type 2 diabetes. SUSTAIN-6 showed the same for injectable semaglutide in type 2 diabetes. REWIND showed a reduction with dulaglutide. SELECT was the most consequential: semaglutide 2.4mg reduced major adverse cardiovascular events by 20% versus placebo in adults with obesity and established cardiovascular disease but without diabetes — the first demonstration that treating obesity pharmacologically reduces cardiovascular events in a non-diabetic population.
Kidney outcomes. The FLOW trial evaluated semaglutide in patients with type 2 diabetes and chronic kidney disease, reporting a reduction in kidney disease progression and related events. This supported the CKD indication now carried on the Ozempic label.
Sleep apnea. Tirzepatide was studied in adults with obesity and moderate to severe obstructive sleep apnea in the SURMOUNT-OSA program, showing significant reduction in apnea-hypopnea index, and Zepbound carries an OSA indication on that basis.
Where the distinction now sits. Tirzepatide’s dedicated cardiovascular outcomes trial, SURPASS-CVOT, reported in late 2025. It enrolled over 13,000 adults with type 2 diabetes and atherosclerotic cardiovascular disease and compared tirzepatide against dulaglutide — an active comparator with its own established cardiovascular benefit, rather than placebo. Over a median follow-up of approximately four years, the primary composite of cardiovascular death, myocardial infarction, or stroke occurred in 12.2% of the tirzepatide group versus 13.1% on dulaglutide, meeting the prespecified criteria for noninferiority but not for superiority. Gastrointestinal adverse events and discontinuations were more frequent with tirzepatide in this population.
The practical reading is narrower than headlines suggest. SURPASS-CVOT establishes cardiovascular safety and noninferiority for tirzepatide in patients who already have type 2 diabetes and established cardiovascular disease. It does not replicate what SELECT demonstrated, which was event reduction in adults with obesity and cardiovascular disease but without diabetes. Semaglutide 2.4mg remains the only agent in the class carrying an FDA label for cardiovascular risk reduction in that non-diabetic population, and for patients whose coverage depends on that specific indication, the distinction is practical rather than academic.
Side Effects and Safety Across the Class
The adverse effect profile is broadly consistent across GLP-1 medications, because it follows directly from the mechanism. Slowed gastric emptying produces gastrointestinal symptoms, and these are by a wide margin the most common reason patients discontinue.
| Category | What Occurs | Clinical Context |
|---|---|---|
| Gastrointestinal | Nausea, vomiting, diarrhea, constipation | Most common; concentrated during dose escalation and usually attenuating with time on a stable dose |
| Thyroid C-cell tumors | Boxed warning on long-acting agents | Based on rodent data; human relevance unknown. Contraindicated with personal or family history of MTC or MEN2 |
| Pancreatitis | Reported across the class | Uncommon but serious. Severe abdominal pain radiating to the back requires immediate evaluation |
| Gallbladder disease | Cholelithiasis, cholecystitis | Associated with rapid weight loss generally, not unique to this class |
| Diabetic retinopathy | Complications in type 2 diabetes | Observed in SUSTAIN-6; patients with existing retinopathy warrant ophthalmologic monitoring |
| Lean mass loss | A share of total weight lost is lean tissue | Expected with any substantial caloric deficit; adequate protein and resistance training mitigate it |
| Pregnancy | Not recommended across the class | Semaglutide labeling advises discontinuation at least 2 months before a planned pregnancy |
Liraglutide, dulaglutide, semaglutide (injectable and oral), extended-release exenatide, and tirzepatide all carry this boxed warning. In rodent studies these molecules caused dose-dependent thyroid C-cell tumors; whether this applies to humans is not known. All are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). Report any new neck lump, hoarseness, difficulty swallowing, or persistent severe abdominal pain to a physician immediately. Short-acting exenatide (Byetta) does not carry this particular boxed warning, but it carries its own contraindications and is not a substitute decision made without a clinician.
Across head-to-head and pivotal data, tirzepatide has shown numerically lower gastrointestinal event rates than semaglutide at weight management doses despite producing greater weight loss — likely a function of its longer five-step escalation schedule rather than a fundamentally gentler mechanism. For a dose-by-dose breakdown of what to expect during escalation, see our complete guide to tirzepatide side effects.
How Clinicians Choose Within the Class
There is no single best GLP-1 medication. The choice is driven by indication, coverage, comorbidity, tolerability history, and patient preference on route and frequency of administration.
Factors That Drive Selection Within the GLP-1 Class
Figure 2. Educational summary only. Medication selection requires individual assessment by a licensed clinician.
Two patterns are worth naming. Patients whose primary goal is maximum weight reduction and who have no competing coverage constraint are generally directed toward dual agonism, on the strength of the SURMOUNT-5 result. Patients with obesity and established cardiovascular disease but no diabetes are generally directed toward semaglutide 2.4mg, because it is the only agent with an approved cardiovascular risk reduction indication in that specific population. For patients who have type 2 diabetes alongside cardiovascular disease, both molecules now have outcomes data behind them and the choice turns on tolerability, glycemic target, and coverage rather than on evidence availability. For a detailed side-by-side of the two most-prescribed molecules, see our comparison of tirzepatide versus semaglutide.
Access, Cost, and Compounded Products
Cost is the most common practical barrier to this class. List prices for brand-name GLP-1 medications run approximately $1,000 to $1,350 per month, and coverage varies widely — many commercial plans cover these drugs for diabetes but exclude them for weight management.
Manufacturer self-pay programs have changed the picture substantially since late 2025. Both major manufacturers now sell directly to cash-paying patients at prices well below list. These programs exclude patients with any government coverage, including Medicare, Medicaid, and TRICARE, and manufacturer copay savings cards carry the same exclusion. Using a copay card with government coverage is not a loophole; it creates real billing and compliance problems. For a full breakdown of pathways and current pricing, see our guide to Ozempic cost without insurance.
The gap between list price and cash price created a market of unverified vendors, international pharmacy sites, and products marketed as research-grade peptides that are not intended for human use. Compounded semaglutide is not available through standard legal channels following the FDA’s February 2025 shortage resolution and subsequent enforcement actions. International pharmacy imports are not FDA-regulated and personal importation of prescription drugs is not lawful. Any offer substantially below the manufacturer’s own self-pay price warrants caution, and any product should be dispensed by a licensed US pharmacy against a valid prescription.
What Is Coming Next
The class is moving in two directions at once: more receptor targets, and easier administration.
Additional targets. Retatrutide, the triple GIP/GLP-1/glucagon agonist, is in late-stage development. CagriSema pairs semaglutide with cagrilintide, an amylin analog, combining incretin and amylin signaling in a single weekly injection. Both remain investigational and neither is FDA-approved.
Oral administration. Rybelsus demonstrated that oral semaglutide is feasible, though absorption is low and dosing conditions are strict. Orforglipron, a non-peptide small-molecule GLP-1 agonist in development, would not carry those absorption constraints if approved, potentially removing both the injection and the cold-chain requirement.
None of this should change a current treatment decision. Investigational agents have no approved indication, no established long-term safety profile, and no legal supply chain, and waiting for a pipeline drug is rarely the right choice for a patient with a present clinical need. For patients starting on currently available therapy, our guide on semaglutide for weight management and our guide to safe use of tirzepatide cover what supervised therapy looks like in practice.
Get a Physician Evaluation for GLP-1 Therapy
Advanced TRT Clinic provides administrative and technology services that connect patients with independent licensed clinicians through Beluga Health, P.A., who provide all clinical evaluation, treatment selection, prior authorization support, and ongoing monitoring. Clinicians can review your metabolic profile, comorbidities, coverage situation, and prior treatment history to determine whether a GLP-1 medication is appropriate and, if so, which product fits your indication. Advanced TRT Clinic is not a pharmacy, does not fill prescriptions, and is not affiliated with, endorsed by, or a distributor for Novo Nordisk, Eli Lilly, or any other manufacturer. All prescribing decisions are made by independent licensed clinicians based on individual patient assessment. Availability varies by state.
